Qezzaqar (catequentinib)

Where it stands

Qezzaqar (catequentinib), developed by CATS Consultants GmbH for the EU, is no longer under regulatory review. The records show the EU marketing authorisation application was withdrawn on 2026-10-30. No approval date is recorded, so the product has never been authorised in the EU on the basis of these records.

The sequence is clear from the two official milestones. On 2026-07-23 the CHMP adopted a negative opinion. Roughly three months later, on 2026-10-30, the application was withdrawn. The proposed indication was the treatment of synovial sarcoma or leiomyosarcoma, both soft tissue sarcomas.

The records do not state the reasons for the negative opinion or the withdrawal. They also do not say whether a re-examination was requested. Any interpretation of why the sponsor withdrew would be speculation and is not offered here.

Regulatory pathway and designations

The product carries an Orphan designation in the EU. In general terms, this designation is granted for conditions that are rare and serious, and it can bring incentives such as protocol assistance and, upon authorisation, market exclusivity. Because the product was not approved, no orphan market exclusivity would have taken effect. The records do not say whether the designation remains on the Community Register or has been, or will be, removed.

A CHMP negative opinion means the Committee concluded that the benefit-risk balance had not been shown to be favourable for the proposed indication. Under standard EU procedure, an applicant can request a re-examination within a defined period after receiving the opinion, and the European Commission normally issues a decision following an opinion. Here, the applicant instead withdrew the application, which ends the procedure without a Commission authorisation decision.

The records do not provide the procedure type (for example, standard versus conditional approval or accelerated assessment), the submission date, or the clinical package. These points cannot be assessed from the available data.

Safety and pharmacovigilance

The records contain no safety data, adverse event information, risk management plan details or pharmacovigilance commitments for catequentinib. No conclusions about its safety profile can be drawn from them.

As the product is not authorised in the EU, there are no marketed-use post-authorisation obligations arising from this application. Whether any ongoing clinical trials or other access programmes exist is not covered by the records.

What to watch

The key point for professionals is that the EU route for this product has closed for now. Watch for the publication of a withdrawal assessment report or related public documents from the EMA, which typically describe the grounds for the Committee's concerns. Such documents would be the first reliable source of the reasons, and they are not part of the current records.

Other items worth monitoring, none of which are covered by the records: whether the sponsor announces a new submission or additional studies, whether the orphan designation status changes, and any regulatory activity in other regions. For anyone developing in synovial sarcoma or leiomyosarcoma, the withdrawal indicates that this agent is not an EU option in the near term.